Esperion Therapeutics (ESPR) Stock Chart & Stock Price History $2.19 +0.02 (+0.92%) (As of 12/20/2024 05:51 PM ET) Add Compare Share Share Chart Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Esperion Therapeutics Stock Price Performance 5 Day Performance-6.01%1 Month Performance-11.34%3 Month Performance+30.36%6 Month Performance-0.90%Year-To-Date Performance-26.76%1 Year Performance-6.01% Receive ESPR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Buy this coin BEFORE Inauguration Day … (Ad)Mark my words … Bitcoin is going to $100,000. BEFORE Trump is inaugurated. And I think it could reach $125,000 by the end of his first month in office.This could be his favorite coin. ESPR Stock Chart for Saturday, December, 21, 2024 ESPR Chart by TradingView Esperion Therapeutics Stock Price History Daily Weekly Monthly Time Frame Custom Range 1 Month 3 Months 6 Months Year-to-Date 1 Year Time Frame * Start Date * End Date Export to Excel DateOpening PriceClosing PriceHighLowVolumeMarket Capitalization12/20/2024$2.17$2.19+0.92%$2.23$2.126.14 million shs$431.51 million12/19/2024$2.16$2.17+0.46%$2.25$2.143.60 million shs$427.57 million12/18/2024$2.46$2.16-12.20%$2.42$2.125.83 million shs$425.60 million12/17/2024$2.33$2.46+5.58%$2.54$2.357.51 million shs$484.71 million12/16/2024$2.25$2.33+3.56%$2.43$2.216.44 million shs$459.09 million12/13/2024$2.55$2.25-11.76%$2.27$1.8433.88 million shs$443.34 million Get the Latest News and Ratings for ESPR and Related StocksEnter your email address below to receive the latest news and analysts' ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. 12/12/2024$2.69$2.55-5.20%$2.72$2.478.22 million shs$502.44 million12/11/2024$3.04$2.69-11.51%$3.09$2.2819.10 million shs$530.04 million12/10/2024$3.83$3.04-20.63%$3.89$2.9713.59 million shs$599.00 million12/09/2024$3.48$3.83+10.06%$3.94$3.355.57 million shs$754.66 million12/06/2024$3.34$3.48+4.19%$3.67$3.395.86 million shs$685.70 million12/05/2024$3.66$3.34-8.74%$3.79$3.287.44 million shs$658.11 million12/04/2024$3.25$3.66+12.62%$3.81$3.3110.91 million shs$721.15 million12/03/2024$3.10$3.25+4.84%$3.29$3.015.48 million shs$640.38 million12/02/2024$2.80$3.10+10.71%$3.44$2.7813.82 million shs$610.82 million11/29/2024$2.54$2.80+10.24%$2.81$2.524.13 million shs$551.71 million11/28/2024$2.54$2.54$2.61$2.465.32 million shs$500.48 million11/27/2024$2.57$2.54-1.17%$2.61$2.465.32 million shs$500.48 million11/26/2024$2.57$2.57$2.61$2.517.57 million shs$506.38 million11/25/2024$2.52$2.57+1.98%$2.62$2.524.42 million shs$506.39 million11/22/2024$2.47$2.52+2.02%$2.54$2.453.16 million shs$496.53 million11/21/2024$2.41$2.47+2.49%$2.51$2.352.72 million shs$486.69 million11/20/2024$2.41$2.41$2.45$2.314.28 million shs$474.87 million Related Companies Galapagos Stock Chart Xencor Stock Chart Evotec Stock Chart Arcutis Biotherapeutics Stock Chart Nurix Therapeutics Stock Chart Kiniksa Pharmaceuticals Stock Chart Arcus Biosciences Stock Chart Immunocore Stock Chart Ocular Therapeutix Stock Chart Mesoblast Stock Chart Receive ESPR Stock News and Ratings via EmailSign-up to receive the latest news and ratings for Esperion Therapeutics and its competitors with MarketBeat's FREE daily newsletter. This page (NASDAQ:ESPR) was last updated on 12/21/2024 by MarketBeat.com Staff From Our PartnersAmazon coin set to soar 25X – starting December 16th?This tiny 3-cent crypto just partnered with one of the biggest companies in the world… Amazon. And one team...True Market Insiders | SponsoredDid You See Trump’s Bombshell Exec. Order 001?Biden broke it... Now Trump is going to fix it. Starting with "Exec. Order 001."Banyan Hill Publishing | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | SponsoredThe #1 Crypto for AIWe’ve issued an urgent landmark trade alert for a new crypto wonder. So, I decided to give you this heads-u...Weiss Ratings | SponsoredVideo: Blindfolded Man Gets Into a Cybertruck… What Happens Next Will Shock You“Hi, I’m Jeff Brown… Even though I can’t see a thing… I’m about to get in this Cybertruck and drive up t...Brownstone Research | SponsoredTrump’s Sending THIS Crypto Higher on PurposeDiscover the coin set to explode before 2025! Trump could trigger THIS crypto coin… Crypto 101 Media | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Esperion Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Esperion Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
